-
公开(公告)号：US20040171876A1
公开(公告)日：2004-09-02
申请号：US10788728
申请日：2004-02-26
Applicant: Bristol-Myers Squibb Company , Bristol-Myers Squibb Company to Women First Healthcare, Inc.
Inventor： Jingyang Zhu , Scott T. Chadwick , Benjamin A. Price , Shannon X. Zhao , Carrie A. Costello , Purushotham Vemishetti
IPC: C07C229/02
CPC classification number: C07C255/29 , C07C227/10 , C07C227/16 , C07C227/18 , C07C227/22 , C07C227/40 , C07C227/42 , C07C253/30 , C07C255/28 , C07C229/26
Abstract: Provided are processes and synthetic intermediates useful for the preparation of null-difluoromethylornithine (DFMO) having the formula 1
-
公开(公告)号：US20250163054A1
公开(公告)日：2025-05-22
申请号：US18839055
申请日：2023-02-17
Applicant: Bristol-Myers Squibb Company
Inventor： David S. Yoon , Chunjian Liu , Alicia Regueiro-Ren , Shoshana L. Posy
IPC: C07D471/04 , A61K31/437 , A61K31/438 , A61K31/4545 , A61K31/496 , C07D519/00
Abstract: Disclosed are compounds of Formulas (I) or a salt thereof, wherein Q, G, R1, R5,a, and R5b are defined herein. Also disclosed are methods of using such compounds as inhibitors of TLR9, and pharmaceutical compositions comprising such compounds. These compounds are useful in treating, preventing, or slowing fibrotic diseases.
-
公开(公告)号：US20250163004A1
公开(公告)日：2025-05-22
申请号：US18976869
申请日：2024-12-11
Applicant: Bristol-Myers Squibb Company
Inventor： Steven H. Spergel , Ryan M. Moslin , Michael Edward Mertzman , Joseph A. Tino , Shoshana L. Posy , Sirish Kaushik Lakkaraju , Zili Xiao , James Kempson
IPC: C07D249/04 , A61K31/501 , A61P25/16 , A61P25/28
Abstract: There are disclosed compounds of the following formula I: or a stereoisomer or pharmaceutically acceptable salt thereof, wherein all substituents are as defined herein, which are useful in the modulation of IL-12, IL-23 and/or IFNα, by acting on Tyk-2 to cause signal transduction inhibition. The compounds of the invention may be useful for treating neurodegenerative diseases or disorders.
-
公开(公告)号：US20250155451A1
公开(公告)日：2025-05-15
申请号：US19025687
申请日：2025-01-16
Applicant: Bristol-Myers Squibb Company
Inventor： Benedetto FARSACI
IPC: G01N33/68 , C07K16/28 , G01N33/574
Abstract: This invention relates to methods for predicting a prognosis of a patient with cancer in need of an anti-cancer treatment comprising measuring a cytokine score from a sample obtained from the patient. In some embodiments, the subject is administered an anti-cancer treatment, e.g., an anti-PD-1 antibody, following the cytokine score measurement. In some embodiments, the cancer is lung cancer.
-
公开(公告)号：US12291517B2
公开(公告)日：2025-05-06
申请号：US18102761
申请日：2023-01-29
Applicant: Bristol-Myers Squibb Company
Inventor： Daniel Richard Roberts
IPC: C07D403/12
Abstract: Disclosed is crystalline Form B of 6-(cyclopropanecarboxamido)-4-((2-methoxy-3-(1-methyl-1H-1,2,4-triazol-3-yl)phenyl) amino)-N-(methyl-d3)pyridazine-3-carboxamide. Form B is the HCl salt of a neat crystalline form. Characterization data for Form B are disclosed.
-
Patent Agency Ranking
公开(公告)号：US20250134996A1
公开(公告)日：2025-05-01
申请号：US18905043
申请日：2024-10-02
Applicant: Bristol-Myers Squibb Company
Inventor： Benedetto FARSACI
IPC: A61K39/395 , A61K31/351 , A61K31/475 , A61K31/655 , A61K39/00 , A61K45/06 , A61P35/00 , C07K16/28
Abstract: This disclosure provides to methods for treating Hodgkin lymphoma in a subject comprising administering to the subject an anti-Programmed Death-1 (PD-1) antibody to a subject, wherein the subject has received at least one prior treatment for Hodgkin lymphoma.
-
公开(公告)号：US12286424B2
公开(公告)日：2025-04-29
申请号：US17998261
申请日：2021-05-10
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Prasada Rao Jalagam , Susheel Jethanand Nara , Manoranjan Panda , Murugesan Natesan , Pratik Devasthale
IPC: C07H19/12 , C07D405/04 , C07D405/14 , C07D487/08
Abstract: The present disclosure relates to compounds of Formula (I), which inhibit Gal-3, and include pharmaceutically acceptable salts, compositions comprising such compounds, and methods using and making such compounds and compositions. (Formula (I))
-
公开(公告)号：US20250129166A1
公开(公告)日：2025-04-24
申请号：US18939765
申请日：2024-11-07
Inventor： Robert J. Johnston , Arvind Rajpal , Paul O. Sheppard , Luis Borges , Andrew Rankin , Keith Sadoon Bahjat , Alan J. Korman , Xiaodi Deng , Lin Hui Su , Ginger Rakestraw , Jason R. Pinckney , David A. Critton , Guodong Chen , Richard Y. Huang , Ekaterina G. Deyanova
Abstract: The present application relates to antibodies specifically binding to the V-domain immunoglobulin-containing suppressor of T-cell activation (VISTA) at acidic pH and their use in cancer treatment. In some embodiments, the antibodies bind specifically to human VISTA at acidic pH, but do not significantly bind to human VISTA at neutral or physiological pH.
-
公开(公告)号：US20250129061A1
公开(公告)日：2025-04-24
申请号：US18968101
申请日：2024-12-04
Applicant: Bristol-Myers Squibb Company
Inventor： Lan-Ying QIN , Zheming RUAN , Ashok Vinayak PURANDARE , Emily Charlotte CHERNEY , James Aaron BALOG , Arvind MATHUR , Samuel J. BONACORSI
IPC: C07D413/14 , A61K31/4545 , A61K45/06 , C07B59/00
Abstract: Disclosed are compounds of Formula (I): or stereoisomers, tautomers, or salts thereof, wherein each R is independently H or D. Also disclosed are methods of using such compounds to decrease the levels of IKZF1-4 proteins, and pharmaceutical compositions comprising the compound. The compounds are useful in the treatment of viral infections and proliferative disorders, such as cancer.
-
公开(公告)号：US12275721B2
公开(公告)日：2025-04-15
申请号：US17762771
申请日：2020-10-02
Applicant: BRISTOL-MYERS SQUIBB COMPANY
Inventor： Jie Chen , Carolyn Diane Dzierba , Junqing Guo , Amy C. Hart , William J. Pitts , Sing-Yuen Sit
IPC: C07D409/04 , C07D403/04 , C07D417/04
Abstract: Compounds having formula (I), and enantiomers, and diastereomers, stereoisomers, pharmaceutically-acceptable salts thereof, are useful as kinase modulators, including RIPK1 modulation. All the variables are as defined herein.
-
-
-
-
-
-
-
-
-
Search Results
2787
records
(took 0.1 seconds)
